CPX Targeting DJ-1 Triggers ROS-induced Cell Death and Protective Autophagy in Colorectal Cancer
暂无分享,去创建一个
Jiang Lan | Y. Bu | Li Zhou | Canhua Huang | Yunlong Lei | Haiyuan Zhang | Xuping Feng | Jing Zhou | Wei Gao | Lu Zhang | Chundong Zhang | Meng Wang | Linli Yu
[1] W. Jin. Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression , 2020, Journal of clinical medicine.
[2] P. Leedman,et al. Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology , 2020, Frontiers in Oncology.
[3] Hao Zhou,et al. Pathological Roles of Mitochondrial Oxidative Stress and Mitochondrial Dynamics in Cardiac Microvascular Ischemia/Reperfusion Injury , 2020, Biomolecules.
[4] M. McKenna,et al. Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs , 2019, The Journal of Pharmacology and Experimental Therapeutics.
[5] Yong‐Chul Kim,et al. Ciclopirox inhibits Hepatitis B Virus secretion by blocking capsid assembly , 2019, Nature Communications.
[6] Yitao Wang,et al. DJ-1 promotes colorectal cancer progression through activating PLAGL2/Wnt/BMP4 axis , 2018, Cell Death & Disease.
[7] L. Morrison,et al. Antifungal drug ciclopirox olamine reduces HSV‐1 replication and disease in mice , 2018, Antiviral research.
[8] Yuquan Wei,et al. Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux , 2018, Autophagy.
[9] Michalis V. Karamouzis,et al. Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models , 2017, Oncotarget.
[10] M. Karamouzis,et al. 74PEffect of ciclopirox olamine in immunotherapy effect by stimulating immunogenic cell death in pancreatic cancer , 2017 .
[11] Jie J. Zheng,et al. Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. , 2017, Cancer research.
[12] A. Jemal,et al. Colorectal cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[13] Y. Odaka,et al. Ciclopirox inhibits cancer cell proliferation by suppression of Cdc25A , 2017, Genes & cancer.
[14] P. Auberger,et al. Autophagy, a key mechanism of oncogenesis and resistance in leukemia. , 2017, Blood.
[15] Yuquan Wei,et al. Antileukemia Effect of Ciclopirox Olamine Is Mediated by Downregulation of Intracellular Ferritin and Inhibition β-Catenin-c-Myc Signaling Pathway in Glucocorticoid Resistant T-ALL Cell Lines , 2016, PloS one.
[16] T. Shen,et al. Repositioning the Old Fungicide Ciclopirox for New Medical Uses. , 2016, Current pharmaceutical design.
[17] Yuquan Wei,et al. PRKAA/AMPK restricts HBV replication through promotion of autophagic degradation , 2016, Autophagy.
[18] Debashis Sahoo,et al. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. , 2016, The New England journal of medicine.
[19] Sangeeta Khare,et al. Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition) , 2016 .
[20] J. Chan,et al. Activation of endogenous antioxidants as a common therapeutic strategy against cancer, neurodegeneration and cardiovascular diseases: A lesson learnt from DJ-1. , 2015, Pharmacology & therapeutics.
[21] A. Chaudhary,et al. Targeting autophagy to overcome drug resistance in cancer therapy. , 2015, Future medicinal chemistry.
[22] T. Mak,et al. DJ-1 links muscle ROS production with metabolic reprogramming and systemic energy homeostasis in mice , 2015, Nature Communications.
[23] Bo Yang,et al. DJ-1 as a human oncogene and potential therapeutic target. , 2015, Biochemical pharmacology.
[24] Yan Luo,et al. Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway , 2014, Oncotarget.
[25] Jin-jian Lu,et al. DJ-1 mediates the resistance of cancer cells to dihydroartemisinin through reactive oxygen species removal. , 2014, Free radical biology & medicine.
[26] M. Minden,et al. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies , 2014, American journal of hematology.
[27] D. Gewirtz. The four faces of autophagy: implications for cancer therapy. , 2014, Cancer research.
[28] M. Mathews,et al. Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation. , 2014, Cancer research.
[29] T. Mak,et al. Modulation of oxidative stress as an anticancer strategy , 2013, Nature Reviews Drug Discovery.
[30] Z. Huang,et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment , 2013, Cell Death and Disease.
[31] P. Agostinis,et al. Autophagy: shaping the tumor microenvironment and therapeutic response. , 2013, Trends in molecular medicine.
[32] T. J. Cook,et al. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease , 2012, Scientific Reports.
[33] Robert Clarke,et al. Guidelines for the use and interpretation of assays for monitoring autophagy , 2012 .
[34] R. Kurzrock,et al. Autophagy as a target for anticancer therapy , 2011, Nature Reviews Clinical Oncology.
[35] Shengbing Huang,et al. The Role of Autophagy in Cancer: Therapeutic Implications , 2011, Molecular Cancer Therapeutics.
[36] William A Weiss,et al. Principles and Current Strategies for Targeting Autophagy for Cancer Treatment , 2011, Clinical Cancer Research.
[37] M. Lotze,et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells , 2011, Leukemia.
[38] David W. Miller,et al. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. , 2011, Human molecular genetics.
[39] Xiuzhen Han,et al. The antitumor activity of the fungicide ciclopirox , 2010, International journal of cancer.
[40] D. Monti,et al. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. , 2010, Drugs.
[41] David S. Park,et al. Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. , 2010, Human molecular genetics.
[42] J. Im,et al. DJ-1 protects against oxidative damage by regulating the thioredoxin/ASK1 complex , 2010, Neuroscience Research.
[43] D. Sargent,et al. Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. , 2010, Seminars in oncology.
[44] J. Dick,et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. , 2009, Blood.
[45] Peng Huang,et al. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? , 2009, Nature Reviews Drug Discovery.
[46] Deepti Malhotra,et al. Decline in Nrf2-regulated Antioxidants in Chronic Obstructive Pulmonary Disease Lungs Due to Loss of Its Positive Regulator, Dj-1 , 2022 .
[47] V. A. Flørenes,et al. Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. , 2008, Human pathology.
[48] T. Mak,et al. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2 , 2006, Proceedings of the National Academy of Sciences.
[49] Y. Kondo,et al. Autophagy and Cancer Therapy , 2006, Autophagy.
[50] Wenbo Zhou,et al. DJ-1 Up-regulates Glutathione Synthesis during Oxidative Stress and Inhibits A53T α-Synuclein Toxicity* , 2005, Journal of Biological Chemistry.
[51] Raymond Sawaya,et al. The role of autophagy in cancer development and response to therapy , 2005, Nature Reviews Cancer.
[52] Xin Zhao,et al. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[53] T. Mak,et al. DJ-1, a novel regulator of the tumor suppressor PTEN. , 2005, Cancer cell.
[54] D. Jäger,et al. [Systemic therapy for colorectal cancer]. , 2005, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.
[55] R. Krüger,et al. Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7) , 2004, Human mutation.
[56] Y. Hod. Differential control of apoptosis by DJ‐1 in prostate benign and cancer cells , 2004, Journal of cellular biochemistry.
[57] M. Schaller,et al. Ciclopirox Olamine Treatment Affects the Expression Pattern of Candida albicans Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors , 2003, Antimicrobial Agents and Chemotherapy.
[58] R. Wenger,et al. The antimycotic ciclopirox olamine induces HIF‐1α stability, VEGF expression, and angiogenesis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[59] Patrizia Rizzu,et al. Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.
[60] H. Kleinman,et al. The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro , 2002, International journal of cancer.
[61] Kohei Miyazono,et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal‐regulating kinase (ASK) 1 , 1998, The EMBO journal.
[62] H. Korting,et al. The hydroxypyridones: a class of antimycotics of its own , 1997, Mycoses.
[63] J. Hardcastle,et al. Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.
[64] R. N. Brogden,et al. Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use. , 1985, Drugs.
[65] E. Schütz,et al. [Studies on the pharmacology and toxicology of ciclopiroxolamine (author's transl)]. , 1981, Arzneimittel-Forschung.
[66] H. Eckert,et al. [Pharmacokinetics and biotransformation of the antimycotic drug ciclopiroxolamine in animals and man after topical and systemic administration]. , 1981, Arzneimittel-Forschung.
[67] HighWire Press,et al. The journal of pharmacology and experimental therapeutics , 1909 .